AU2001296001A1 - Process for producing b-form nateglinide crystal - Google Patents

Process for producing b-form nateglinide crystal

Info

Publication number
AU2001296001A1
AU2001296001A1 AU2001296001A AU9600101A AU2001296001A1 AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1 AU 2001296001 A AU2001296001 A AU 2001296001A AU 9600101 A AU9600101 A AU 9600101A AU 2001296001 A1 AU2001296001 A1 AU 2001296001A1
Authority
AU
Australia
Prior art keywords
producing
nateglinide
type crystals
crystals
nateglinide crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296001A
Other languages
English (en)
Inventor
Makoto Maruo
Yukiko Matsuzawa
Kazuo Miyazaki
Shigehiro Nishina
Michito Sumikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001296001A1 publication Critical patent/AU2001296001A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001296001A 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal Abandoned AU2001296001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
JP2000-324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (1)

Publication Number Publication Date
AU2001296001A1 true AU2001296001A1 (en) 2002-05-06

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296001A Abandoned AU2001296001A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Country Status (18)

Country Link
US (2) US20030229249A1 (https=)
EP (1) EP1334964B1 (https=)
JP (1) JP4225057B2 (https=)
KR (1) KR100810930B1 (https=)
CN (1) CN100422143C (https=)
AT (1) ATE370115T1 (https=)
AU (1) AU2001296001A1 (https=)
BR (1) BR0114846A (https=)
CA (1) CA2426745C (https=)
CY (1) CY1106839T1 (https=)
DE (1) DE60130014T2 (https=)
DK (1) DK1334964T3 (https=)
ES (1) ES2288997T3 (https=)
MX (1) MXPA03003575A (https=)
PT (1) PT1334964E (https=)
RU (1) RU2275354C2 (https=)
TW (1) TWI293290B (https=)
WO (1) WO2002034713A1 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070104953A (ko) * 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
PT1334962E (pt) * 2000-10-18 2007-10-09 Ajinomoto Kk ''processo de preparação de acilfenilalaninas''
CA2425538C (en) * 2000-10-18 2010-10-12 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
ATE429217T1 (de) * 2000-10-24 2009-05-15 Ajinomoto Kk Nateglinid enthaltende hydrophile arzneimittelpräparate
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
EP2264004A1 (en) * 2002-04-15 2010-12-22 Ajinomoto Co., Inc. New nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
EP1467964A1 (en) * 2002-07-18 2004-10-20 Teva Pharmaceutical Industries Limited Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
DE60310734T2 (de) * 2003-11-26 2007-10-11 A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A. Verfahren zur Herstellung von Nateglinid in der B-Form
KR20070009726A (ko) * 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
AU2011266820A1 (en) 2010-06-14 2013-01-24 Cipla Limited A process for the preparation of nateglinide
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
AU718350B2 (en) * 1996-11-15 2000-04-13 Ajinomoto Co., Inc. Tablet composition
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
CZ20022294A3 (cs) * 1999-12-28 2002-11-13 Ajinomoto Co., Inc. Antidiabetický preparát k orálnímu uľití
KR20070104953A (ko) * 2000-03-17 2007-10-29 아지노모토 가부시키가이샤 신경 장애용 약제
CA2425538C (en) * 2000-10-18 2010-10-12 Ajinomoto Co., Inc. Methods for producing nateglinide crystals
PT1334962E (pt) * 2000-10-18 2007-10-09 Ajinomoto Kk ''processo de preparação de acilfenilalaninas''
RU2271805C2 (ru) * 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
RU2275354C2 (ru) 2006-04-27
DK1334964T3 (da) 2007-09-24
CY1106839T1 (el) 2012-05-23
EP1334964A1 (en) 2003-08-13
KR20030059212A (ko) 2003-07-07
ATE370115T1 (de) 2007-09-15
EP1334964B1 (en) 2007-08-15
PT1334964E (pt) 2007-09-20
WO2002034713A1 (en) 2002-05-02
BR0114846A (pt) 2004-02-25
MXPA03003575A (es) 2003-07-14
US20070232829A1 (en) 2007-10-04
TWI293290B (https=) 2008-02-11
CA2426745C (en) 2009-09-15
JPWO2002034713A1 (ja) 2004-03-04
DE60130014D1 (de) 2007-09-27
US20030229249A1 (en) 2003-12-11
CN100422143C (zh) 2008-10-01
ES2288997T3 (es) 2008-02-01
KR100810930B1 (ko) 2008-03-10
CA2426745A1 (en) 2003-04-23
JP4225057B2 (ja) 2009-02-18
EP1334964A4 (en) 2005-09-28
CN1483018A (zh) 2004-03-17
DE60130014T2 (de) 2008-05-08
US7544834B2 (en) 2009-06-09

Similar Documents

Publication Publication Date Title
AU2001296001A1 (en) Process for producing b-form nateglinide crystal
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
IL154122A0 (en) Crystalline and pure modafinil, and process of preparing the same
ZA200210248B (en) Expandable graphite intercalation compounds, method for synthesizing them and their use.
AU2001253376A1 (en) Improved process for the conversion of an aqueous biomass hydrolyzate into fuelsor chemicals by the selective removal of fermentation inhibitors
EP1318201A4 (en) PROCESS FOR PRODUCING PURIFIED ANTHOCYANIN AND CRYSTALLINE ANTHOCYANIN
DE50305423D1 (de) Mutter und verfahren zu ihrer herstellung
WO2002044194A1 (en) L-nucleic acid derivatives and processes for the synthesis thereof
CA2347882A1 (en) Production of amides and/or acids from nitriles
WO2003011228A3 (en) Purification and crystalline forms of zaleplon
BR0014993A (pt) Processo para a produção de n-metil pirrolidona obtida pela reação de gama butirolactona e metilaminas mistas
CA2347853A1 (en) Process for racemization of [2-(2-thienyl)ethylamino] (2-halogenophenyl)acetamides
CA2326441A1 (en) Process for purification of a cephalosporin derivative
CA2234650A1 (en) Method for producing calcium borate
DE60235318D1 (de) Dikarbonsäuresalze des acetyl-l-carnitins und verfahren zu ihrer herstellung
DK1095009T3 (da) Fremgangsmåde til fremstilling af 4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-carboxylsyre
AU2321900A (en) Process for the preparation of alpha-aminoketones
NO20014885L (no) Fremgangsmåte til fremstilling av en amidforbindelse
CA2363875A1 (en) Method crystallising n-(4-trifluoromethylphenyl)-5-methyl-isoxazole-4-carboxamide
EP1431278A4 (en) METHOD FOR PRODUCING (2-NITROPHENYL) ACETONITRILE DERIVATIVES AND ASSOCIATED INTERMEDIATES
EP1367050A4 (en) 2-METHYLINDOLE-4-ACETIC ACID, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING INTERMEDIATE PRODUCT THEREOF
WO2003057665A1 (en) Process for producing crystal of benzenesulfonamide derivative, and novel crystal of intermediate therefor and process for producing the same
EP1067196A4 (en) METHOD FOR PRODUCING LYSOSPHINGOLIPIDS
DE60023232D1 (de) Kristallisierung von Alpha-L-Aspartyl-L-Phenylalaninmethylester aus übersättigten Lösungen
WO2003087118A3 (de) Verfahren zur herstellung von beta-l-2'deoxy-thymidin